GlucoTrack Inc. Reports Positive First-in-Human Study Results for Continuous Blood Glucose Monitor

Summary

GlucoTrack Inc. announced positive results from its first human study of the continuous blood glucose monitoring device (CBGM) at the American Diabetes Association’s 85th Scientific Sessions. The study confirmed the safety and accuracy of the device, with a mean absolute relative difference (MARD) of 7.7%, on par with leading systems. A long-term feasibility study is planned for Q3 2025. The device aims to provide a less invasive diabetes management option, with 92% of measurements in the green zone of the Diabetes Technology Association error grid. It is still under research under federal law.Reuters

Impact Analysis

The announcement of GlucoTrack’s positive human study results represents a significant product milestone for the company, indicating the potential of their continuous blood glucose monitoring device (CBGM) to enter and compete in the diabetes management market. The first-order effects include potential growth prospects and market advantages, as the device’s accuracy is comparable to leading systems, potentially attracting attention from investors and partners interested in innovative diabetes solutions. However, risks involve regulatory hurdles, as the device is still under research, and the need for further studies to confirm long-term efficacy and safety. The planned long-term feasibility study scheduled for Q3 2025 is crucial for advancing toward commercialization. Second-order effects might impact industry peers and competitors, prompting advancements or competition in diabetes management technologies. Investment opportunities could arise from strategic partnerships or licensing deals, given the device’s promising initial results.Reuters